The Simms/Mann - UCLA Center for Integrative Oncology is part of UCLA's Jonsson Comprehensive Cancer Center and UCLA Oncology. To find out more about research opportunities and medical oncology care, please visit these sites.
simmsmanncenter@mednet.ucla.edu

Posts

Phone: (310) 794-6644 Fax: (310) 794-9615
Mon - Fri: 8:00AM - 5:00PM Sat - Sun: Closed
Email simmsmanncenter@mednet.ucla.edu

Insights Into Cancer – August 8, 2017

Sarcomas: Treating Rare Cancers with Targeted Therapy

Presented by Arun Singh, MD

About the Lecture

Sarcomas are a rare and complex group of malignancies with only ~13000 cases yearly in the United States. The current clinical management requires a specialized and multidisciplinary approach and is currently evolving. All too often, patients dealing with the diagnosis of sarcoma are also burdened by the paucity of information regarding the approach to treating this group of diseases. Moreover, navigating the landscape regarding the optimal treatment, whether chemotherapy, surgery or radiation therapy, can be a daunting process. Dr. Singh discusses the important details about organizing and understanding these malignancies and how families can gain more insight about sarcomas. The important contribution of basic research into fighting these diseases is presented along with novel clinical trials currently being pursued.

About the Speaker

Arun Singh, MD is an Assistant Professor in the Department of Medicine, Division of Hematology/Oncology at the David Geffen School of Medicine UCLA. Dr. Singh is a Hematologist and Medical Oncologist whose practice focuses on the treatment of bone and soft tissue sarcomas. Dr. Singh’s research focus is on developing novel therapies for patients with sarcomas. In the preclinical setting, he works on elucidating the mechanisms contributing to the promotion of growth in cancer cells and optimizing the use of targeted therapy in specific sarcoma subtypes. The insights gained from these efforts are then translated into the clinic in the form of new drugs in early stage Phase I and II clinical trials for sarcomas where there is an unmet clinical need.

Contact us for more information or book an appointment